MSH2 and prostate carcinoma: We found a significantly higher incidence of prostate cancer in men with pathogenic variants in MSH2 and MSH6 compared with non-carrier controls, supporting that the risk of prostate cancer is increased with Lynch syndrome, and specifically with MSH2 and MSH6.